(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 18.23% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.97%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Supernus Pharmaceuticals's revenue in 2026 is $718,952,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $50,804,920,315, with the lowest SUPN revenue forecast at $48,259,232,827, and the highest SUPN revenue forecast at $52,758,091,986. On average, 8 Wall Street analysts forecast SUPN's revenue for 2027 to be $60,000,143,904, with the lowest SUPN revenue forecast at $54,528,153,813, and the highest SUPN revenue forecast at $64,376,354,016.
In 2028, SUPN is forecast to generate $68,234,328,720 in revenue, with the lowest revenue forecast at $61,612,431,840 and the highest revenue forecast at $73,071,192,528.